$7.83 Billion is the total value of Baker Brothers Advisors's 95 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 27.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Sell | Incyte Corporation | $1,863,369,325 | -9.6% | 30,738,524 | -15.0% | 23.81% | -7.9% |
| BGNE | BeiGene, Ltd.sponsored adr | $1,507,864,535 | -8.8% | 10,568,897 | 0.0% | 19.27% | -7.1% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $696,766,135 | -12.1% | 42,877,916 | +0.0% | 8.90% | -10.4% |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $553,201,134 | +5.2% | 1,974,590 | +0.2% | 7.07% | +7.1% |
| RVMD | Buy | Revolution Medicines, Inc. | $293,756,383 | +20.7% | 7,569,090 | +0.3% | 3.75% | +23.0% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $262,716,867 | -5.2% | 6,398,365 | 0.0% | 3.36% | -3.5% | |
| INSM | Buy | Insmed Incorporated | $239,594,546 | +2474.7% | 3,576,038 | +942.6% | 3.06% | +2517.1% |
| BCYC | Buy | Bicycle Therapeutics plcsponsored ads | $190,255,190 | +54.6% | 9,399,960 | +90.2% | 2.43% | +57.4% |
| SMMT | New | Summit Therapeutics Inc. | $181,133,332 | – | 23,222,222 | +100.0% | 2.32% | – |
| KYMR | Kymera Therapeutics, Inc. | $178,978,451 | -25.7% | 5,995,928 | 0.0% | 2.29% | -24.4% | |
| EWTX | Edgewise Therapeutics, Inc. | $105,179,463 | -1.3% | 5,840,059 | 0.0% | 1.34% | +0.6% | |
| ALKS | New | Alkermes plc | $100,780,199 | – | 4,181,751 | +100.0% | 1.29% | – |
| New | Insmed Incorporatednote 0.75% 6/1/2028 | $90,413,500 | – | 42,850,000 | +100.0% | 1.16% | – | |
| REPL | Buy | Replimune Group, Inc. | $90,408,024 | +15.9% | 10,045,336 | +5.2% | 1.16% | +18.1% |
| DNLI | Denali Therapeutics Inc. | $86,649,958 | +13.2% | 3,731,695 | 0.0% | 1.11% | +15.2% | |
| ABCL | AbCellera Biologics Inc. | $81,475,894 | -34.7% | 27,525,640 | 0.0% | 1.04% | -33.4% | |
| NRIX | Nurix Therapeutics, Inc. | $81,019,949 | +42.0% | 3,882,125 | 0.0% | 1.04% | +44.6% | |
| IMTX | Immatics N.V. | $74,872,285 | +10.6% | 6,443,398 | 0.0% | 0.96% | +12.6% | |
| Entrada Therapeutics, Inc. | $69,337,921 | +0.6% | 4,865,819 | 0.0% | 0.89% | +2.4% | ||
| RARE | Ultragenyx Pharmaceutical Inc. | $60,275,082 | -12.0% | 1,466,547 | 0.0% | 0.77% | -10.4% | |
| STOK | Buy | Stoke Therapeutics, Inc. | $59,017,665 | +29.8% | 4,368,443 | +29.7% | 0.75% | +32.3% |
| New | Insmed Incorporatednote 1.75% 1/15/2025 | $56,192,307 | – | 32,887,000 | +100.0% | 0.72% | – | |
| New | Kiniksa Pharmaceuticals International, plc | $52,618,090 | – | 2,818,323 | +100.0% | 0.67% | – | |
| IMCR | Immunocore Holdings plcads | $51,354,127 | -47.9% | 1,515,318 | 0.0% | 0.66% | -46.9% | |
| ARGX | Sell | argenx SEsponsored adr | $48,123,196 | -19.2% | 111,904 | -26.0% | 0.62% | -17.7% |
| KOD | Kodiak Sciences Inc. | $40,679,652 | -55.3% | 17,310,490 | 0.0% | 0.52% | -54.5% | |
| XENE | Xenon Pharmaceuticals Inc. | $38,743,544 | -9.4% | 993,679 | 0.0% | 0.50% | -7.8% | |
| PRLD | Prelude Therapeutics Inc. | $38,571,769 | -19.6% | 10,123,824 | 0.0% | 0.49% | -18.1% | |
| IDYA | IDEAYA Biosciences, Inc. | $37,291,139 | -20.0% | 1,062,123 | 0.0% | 0.48% | -18.5% | |
| CERS | Cerus Corporation | $34,280,117 | -6.9% | 19,477,339 | 0.0% | 0.44% | -5.2% | |
| Sera Prognostics, Inc. | $32,171,642 | -34.9% | 5,434,399 | 0.0% | 0.41% | -33.7% | ||
| KRYS | Krystal Biotech, Inc. | $31,206,680 | +3.2% | 169,934 | 0.0% | 0.40% | +5.3% | |
| CELC | Buy | Celcuity Inc. | $30,712,140 | -8.4% | 1,874,978 | +20.8% | 0.39% | -6.9% |
| Sell | Roivant Sciences Ltd. | $29,582,428 | -62.1% | 2,798,716 | -62.3% | 0.38% | -61.4% | |
| IGMS | Buy | IGM Biosciences, Inc. | $28,100,471 | -28.8% | 4,090,316 | +0.0% | 0.36% | -27.5% |
| CERE | Sell | Cerevel Therapeutics Holdings, Inc. | $27,951,913 | -58.7% | 683,588 | -57.3% | 0.36% | -57.9% |
| AKRO | Sell | Akero Therapeutics, Inc. | $25,737,544 | -62.4% | 1,097,082 | -59.6% | 0.33% | -61.7% |
| DYN | Buy | Dyne Therapeutics, Inc. | $23,718,268 | +193.1% | 672,096 | +135.8% | 0.30% | +200.0% |
| New | Alumis Inc. | $20,781,250 | – | 1,562,500 | +100.0% | 0.27% | – | |
| GLUE | Monte Rosa Therapeutics, Inc. | $18,386,195 | -47.0% | 4,916,095 | 0.0% | 0.24% | -46.0% | |
| MRUS | New | Merus N.V. | $17,751,000 | – | 300,000 | +100.0% | 0.23% | – |
| Neurogene Inc. | $16,594,386 | -28.5% | 456,015 | 0.0% | 0.21% | -27.1% | ||
| TScan Therapeutics, Inc. | $16,291,033 | -26.3% | 2,784,792 | 0.0% | 0.21% | -24.9% | ||
| SANA | Sana Biotechnology, Inc. | $12,999,982 | -45.4% | 2,380,949 | 0.0% | 0.17% | -44.5% | |
| IMVT | Buy | Immunovant, Inc. | $12,268,555 | -10.7% | 464,718 | +9.3% | 0.16% | -8.7% |
| XNCR | Xencor, Inc. | $10,325,009 | -14.5% | 545,431 | 0.0% | 0.13% | -12.6% | |
| Buy | Neumora Therapeutics, Inc. | $10,170,118 | +16.7% | 1,034,600 | +63.2% | 0.13% | +19.3% | |
| FATE | Buy | Fate Therapeutics, Inc. | $9,832,692 | -26.3% | 2,997,772 | +64.9% | 0.13% | -24.6% |
| 2seventy bio, Inc. | $9,615,475 | -28.0% | 2,497,526 | 0.0% | 0.12% | -26.8% | ||
| BMEA | Biomea Fusion, Inc. | $9,490,271 | -69.9% | 2,108,949 | 0.0% | 0.12% | -69.4% | |
| CLDX | Celldex Therapeutics, Inc. | $9,165,304 | -11.8% | 247,644 | 0.0% | 0.12% | -10.0% | |
| TSHA | Taysha Gene Therapies, Inc. | $8,970,653 | -22.0% | 4,004,756 | 0.0% | 0.12% | -20.1% | |
| ATHA | Athira Pharma, Inc. | $8,357,589 | -3.3% | 3,153,807 | 0.0% | 0.11% | -0.9% | |
| VERV | Verve Therapeutics, Inc. | $8,254,666 | -63.3% | 1,691,530 | 0.0% | 0.10% | -62.8% | |
| RLAY | Relay Therapeutics, Inc. | $7,563,963 | -21.4% | 1,160,117 | 0.0% | 0.10% | -19.8% | |
| MIRM | Mirum Pharmaceuticals, Inc. | $6,512,374 | +36.1% | 190,476 | 0.0% | 0.08% | +38.3% | |
| Tango Therapeutics, Inc. | $6,435,000 | +8.1% | 750,000 | 0.0% | 0.08% | +9.3% | ||
| Buy | KALA BIO, Inc. | $6,319,565 | +197.4% | 891,335 | +234.3% | 0.08% | +200.0% | |
| New | DBV Technologies S.A.sponsored adr | $5,853,012 | – | 7,307,131 | +100.0% | 0.08% | – | |
| DSGN | Buy | Design Therapeutics, Inc. | $5,679,235 | -15.2% | 1,695,294 | +2.0% | 0.07% | -13.1% |
| Praxis Precision Medicines, Inc. | $5,440,205 | -32.2% | 131,533 | 0.0% | 0.07% | -30.7% | ||
| New | Contineum Therapeutics, Inc.cl a | $5,503,125 | – | 312,500 | +100.0% | 0.07% | – | |
| CRSP | New | CRISPR Therapeutics AGnamen akt | $5,401,000 | – | 100,000 | +100.0% | 0.07% | – |
| Prime Medicine, Inc. | $5,286,315 | -26.6% | 1,028,466 | 0.0% | 0.07% | -24.4% | ||
| CNTA | New | Centessa Pharmaceuticals plcsponsored ads | $4,959,384 | – | 549,212 | +100.0% | 0.06% | – |
| New | HOOKIPA Pharma Inc. | $4,810,240 | – | 8,128,151 | +100.0% | 0.06% | – | |
| Sagimet Biosciences Inc. | $4,726,091 | -36.9% | 1,381,898 | 0.0% | 0.06% | -36.2% | ||
| CRNX | New | Crinetics Pharmaceuticals, Inc. | $4,654,890 | – | 103,927 | +100.0% | 0.06% | – |
| Talis Biomedical Corporation | $4,402,992 | -1.0% | 508,323 | 0.0% | 0.06% | 0.0% | ||
| OPT | Sell | Opthea Limitedsponsored ads | $4,195,090 | -53.1% | 2,173,622 | -0.2% | 0.05% | -51.8% |
| ALEC | New | Alector, Inc. | $4,209,779 | – | 927,264 | +100.0% | 0.05% | – |
| New | Skye Bioscience, Inc. | $4,005,000 | – | 500,000 | +100.0% | 0.05% | – | |
| PCVX | Vaxcyte, Inc. | $3,691,306 | +10.5% | 48,885 | 0.0% | 0.05% | +11.9% | |
| ARCT | New | Arcturus Therapeutics Holdings Inc. | $3,684,861 | – | 151,329 | +100.0% | 0.05% | – |
| GBIO | Buy | Generation Bio Co. | $3,403,619 | +125.3% | 1,206,957 | +225.1% | 0.04% | +126.3% |
| Enliven Therapeutics, Inc. | $2,683,647 | +32.9% | 114,833 | 0.0% | 0.03% | +36.0% | ||
| ADAP | Sell | Adaptimmune Therapeutics plcsponsored adr | $2,284,868 | -86.6% | 2,343,695 | -78.3% | 0.03% | -86.4% |
| Leap Therapeutics, Inc. | $2,297,463 | -26.3% | 1,172,175 | 0.0% | 0.03% | -25.6% | ||
| MRSN | Mersana Therapeutics, Inc. | $2,183,091 | -55.1% | 1,086,115 | 0.0% | 0.03% | -54.1% | |
| IPSC | Century Therapeutics, Inc. | $2,033,523 | -39.0% | 797,460 | 0.0% | 0.03% | -38.1% | |
| NewAmsterdam Pharma Company N.V.ordinary shares | $1,860,047 | -18.8% | 96,827 | 0.0% | 0.02% | -17.2% | ||
| SAGE | Sell | Sage Therapeutics, Inc. | $1,857,342 | -75.7% | 171,026 | -58.0% | 0.02% | -75.0% |
| vTv Therapeutics, Inc.cl a | $1,718,565 | -24.9% | 97,314 | 0.0% | 0.02% | -24.1% | ||
| CMPX | Compass Therapeutics, Inc. | $1,557,630 | -49.5% | 1,557,630 | 0.0% | 0.02% | -48.7% | |
| TARA | Buy | Protara Therapeutics, Inc. | $1,116,611 | +39.5% | 536,832 | +168.9% | 0.01% | +40.0% |
| PFE | Pfizer Inc. | $979,300 | +0.8% | 35,000 | 0.0% | 0.01% | +8.3% | |
| AVTE | Sell | Aerovate Therapeutics, Inc. | $1,044,039 | -97.9% | 628,939 | -62.6% | 0.01% | -97.9% |
| ACHL | Sell | Achilles Therapeutics plcsponsored ads | $903,645 | -40.2% | 1,108,767 | -8.3% | 0.01% | -36.8% |
| ALGS | Aligos Therapeutics, Inc. | $726,740 | -64.3% | 2,076,400 | 0.0% | 0.01% | -65.4% | |
| PMVP | PMV Pharmaceuticals, Inc. | $521,679 | -4.7% | 322,024 | 0.0% | 0.01% | 0.0% | |
| BCRX | Sell | BioCryst Pharmaceuticals, Inc. | $468,308 | -99.1% | 75,778 | -99.3% | 0.01% | -99.1% |
| Acrivon Therapeutics, Inc. | $306,733 | -18.9% | 52,885 | 0.0% | 0.00% | -20.0% | ||
| FHTX | Foghorn Therapeutics Inc. | $258,905 | -14.3% | 45,027 | 0.0% | 0.00% | -25.0% | |
| Tyra Biosciences, Inc. | $169,606 | -2.5% | 10,607 | 0.0% | 0.00% | 0.0% | ||
| Surrozen, Inc.w exp 8/11/2026 | $13,833 | -45.0% | 833,333 | 0.0% | 0.00% | – | ||
| ISR | Exit | Perspective Therapeutics, Inc. | $0 | – | -149,787 | -100.0% | -0.00% | – |
| CABA | Exit | Cabaletta Bio, Inc. | $0 | – | -13,331 | -100.0% | -0.00% | – |
| Exit | Mural Oncology plc | $0 | – | -222,503 | -100.0% | -0.01% | – | |
| FDMT | Exit | 4D Molecular Therapeutics, Inc. | $0 | – | -100,000 | -100.0% | -0.04% | – |
| ALPN | Exit | Alpine Immune Sciences, Inc. | $0 | – | -81,578 | -100.0% | -0.04% | – |
| HOOK | Exit | HOOKIPA Pharma Inc. | $0 | – | -8,128,151 | -100.0% | -0.07% | – |
| DBVT | Exit | DBV Technologies S.A.sponsored adr | $0 | – | -14,614,264 | -100.0% | -0.14% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals, Ltd. | $0 | – | -2,809,577 | -100.0% | -0.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 45 | Q2 2024 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 45 | Q2 2024 | 15.3% |
| BioCryst Pharmaceuticals, Inc. | 45 | Q2 2024 | 1.7% |
| Cerus Corporation | 45 | Q2 2024 | 0.9% |
| Insmed Incorporated | 45 | Q2 2024 | 3.1% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| Mirati Therapeutics, Inc. | 42 | Q4 2023 | 2.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| DBV Technologies S.A. | 38 | Q1 2024 | 1.9% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| KALA BIO, Inc. | June 28, 2024 | 891,335 | 20.0% |
| Entrada Therapeutics, Inc. | June 26, 2024 | 4,865,819 | 13.2% |
| HOOKIPA Pharma Inc. | June 14, 2024 | 9,813,151 | 10.0% |
| INCYTE CORP | June 14, 2024 | 30,849,401 | 16.1% |
| BICYCLE THERAPEUTICS plc | May 28, 2024 | 9,399,960 | 19.9% |
| TScan Therapeutics, Inc. | April 23, 2024 | 2,828,938 | 6.1% |
| IGM Biosciences, Inc. | March 28, 2024 | 4,145,706 | 12.4% |
| MADRIGAL PHARMACEUTICALS, INC. | March 25, 2024 | 2,070,544 | 10.0% |
| vTv Therapeutics Inc. | March 05, 2024 | 122,664 | 5.0% |
| 2seventy bio, Inc. | February 14, 2024 | 2,527,672 | 5.0% |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-10-10 |
| 4 | 2024-10-08 |
| SC 13D/A | 2024-10-08 |
| 4 | 2024-10-02 |
| 4 | 2024-10-02 |
| N-PX | 2024-08-30 |
| 4 | 2024-08-22 |
| SC 13D/A | 2024-08-22 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-07-02 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.